AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01411670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Activated protein C
Description: Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours
Study NCT01411670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Standard treatment
Study NCT03301428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrain pain educational website
Description: Patients in this group will be invited to consult an educational website developped for patients with chronic pain
Study NCT03301428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet
Description: Patients in this group will be invited toread an educational booklet developped for patients with chronic pain
Study NCT03179839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy
Description: The intervention will be carried out according to the handbook of the Dr. Didonna. There is a Session Agenda from Dr. Didonna for the use of the Instructor and session handouts for the participants. Some records of mindfulness practices will be given to participants for facilitating practice between sessions. Before each session, the instructor needs to review the session agenda and prepare copies of handouts for participants.~MBCT instructors were experienced psychotherapists and psychiatrists with several years' expertise in OCD treatment. They had been trained by one of the founders of MBCT, Mark Williams and the founder of MBCT for OCD, Fabrizio Didonna. Supervision will be provided by Dr.Didonna.
Study NCT03179839 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psycho-education Program
Description: As a widely used placebo control condition, the Psycho-Education Program can play an active role through the psychological suggestion and forward thinking mostly. It is designed to be similar with MBCT in level of structure, setting and other non-specific effects of psychological intervention. All instructors will be qualified graduate students who major in clinical psychology with training in cognitive behavioral therapy and psychodynamic therapy.
Study NCT03179839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline, fluvoxamine
Description: The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
Study NCT04686903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epiduroscopy treatment
Description: Device Epiduroscop, procedure mecahnical lysis, laser, radiofrequency + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline) Follow-up: before procedure, 6 months and 12 months after procedure
Study NCT04686903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Racz catheter epidural procedure
Description: Device Racz catheter, two procedures during clinical trial observation~* First procedure after enrolment into the study mechanical lysis and drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 6 months mechanical lysis + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)
Study NCT04686903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal epidural block
Description: Technique Caudal epidural block~Three procedures during clinical trial observation :~* First procedure after enrolment into the study drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 4 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)~* Third procedure after 8 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)
Study NCT00833989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK249320
Description: I.V. infusion
Study NCT00833989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo
Study NCT04084808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Solution ingestion
Description: Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
Study NCT04084808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solution ingestion
Description: Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
Study NCT04084808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Solution ingestion
Description: Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
Study NCT04084808 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive flexibility
Description: Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise.
Study NCT04084808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive flexibility
Description: Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise.
Study NCT00588133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Loading dose: 6.6 mg/kg Prime dose: 50 mg for 2.5 Liter circuit (assuming 1 L/kg Vd in prime fluids), 40 mg for 2 Liter circuit Rate of infusion: 6 mg/kg/hr~Renal Insufficiency (normal loading dose and prime dose):~Serum Creatinine = 1.6-3.3: reduce infusion to 4.5 mg/kg/hr Serum Creatinine = 3.3-6.6: reduce infusion to 3.0 mg/kg/hr Serum Creatinine = >6.6: reduce infusion to 1.5 mg/kg/hr
Study NCT00588133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: 10 mg/kg tranexamic acid given over 20 minutes followed by an infusion of 1 mg/kg/hr
Study NCT03966300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-faceted knowledge translation intervention
Description: The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
Study NCT03003715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scans
Description: Two 90 minute scans whose maximum radiological dose is 15 mCi \[11 C\] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.
Study NCT03379727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Induction Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for 1 - 2 cycles; a cycle = 28 days; Consolidation Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for up to 4 cycles; Maintenance Phase: Continuous dosing (days 1 - 28) for up yo 12 cycles or until relapse, unacceptable toxicity, death, physician's decision, subject/guardian decision, protocol deviation, study termination by Sponsor, lost to follow-up, technical problems, pregnancy, subject withdrew consent, or until the end of study, whichever event occurred first.
Study NCT03003715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: In active tDCS, a 2 milli-amp transcranial direct current stimulation is for 20 minutes.
Study NCT03379727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction Phase (standard dose) (7 + 3 arm): 100-200 mg/m2/day by Continuous intravenous infusion (CIVI) days 1-7 (168 hours infusion); Induction Phase (5 + 2 arm): 100 mg/m2/day by CIVI days 1-5; Consolidation Phase: 1-3 g/m2 infusion over 3 hours every 12 h on days 1, 3 and 5, up to 4 cycles based on age and per investigator discretion
Study NCT03379727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline ((daunorubicin or idarubicin): Induction Phase only
Description: daunorubicin (7 + 3 arm): 60-90 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); daunorubicin (5 + 2 arm): 60 mg/m2/day by IV push on days 1-2; idarubicin (7 + 3 arm): 12 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); idarubicin (5 + 2 arm): 12 mg/m2/day by IV push on days 1-2
Study NCT02899182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide NO
Description: The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
Study NCT02899182 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: O2
Description: the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
Study NCT01806051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.
Study NCT01783990 — intervention group
Intervention type: DRUG
Intervention: Hydroxyurea
Description: Parents and child's doctor may plan to use or not to use hydroxyurea.
Study NCT04084808 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive flexibility
Description: Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise.
Study NCT04084808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain oxygenation
Description: Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~\[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). \] Measured with near-infrared spectroscopy (NIRS).
Study NCT04084808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain oxygenation
Description: Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~\[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). \] Measured with near-infrared spectroscopy (NIRS).
Study NCT04084808 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Brain oxygenation
Description: Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~\[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). \] Measured with near-infrared spectroscopy (NIRS).
Study NCT04084808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palatability
Description: Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
Study NCT04084808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palatability
Description: Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
Study NCT00251238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Description: daily Ginkgo biloba extract EGb 761
Study NCT00251238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo biloba extract EGb 761
Description: daily Ginkgo biloba extract EGb 761
Study NCT04084808 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Palatability
Description: Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
Study NCT04084808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood glucose
Description: Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
Study NCT04084808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood glucose
Description: Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
Study NCT04084808 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood glucose
Description: Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
Study NCT04084808 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perceived exertion
Description: Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, \& Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
Study NCT04084808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceived exertion
Description: Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, \& Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
Study NCT04084808 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Perceived exertion
Description: Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, \& Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
Study NCT04084808 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training bouts
Description: 6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
Study NCT04084808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training bouts
Description: 6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
Study NCT04084808 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: High Intensity Interval Training bouts
Description: 6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
Study NCT02000245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: verbal expression for compassion
Description: The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)
Study NCT02000245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: touch
Description: The doctor going to perform bronchoscopy puts a hand on the patient's shoulder
Study NCT03461068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester
Description: Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour oral glucose tolerance test.
Study NCT03461068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute ingestion of a taste-matched placebo prior a 2-hour oral glucose tolerance test.
Study NCT00941187 — intervention group
Intervention type: OTHER
Intervention: diffusion NO/CO method
Description: pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
Study NCT03003715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.
Study NCT03003715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham tDCS (prior to real tDCS)
Description: For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.
Study NCT04642495 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual acuity testing with SW , Landolt-C and Tumbling-E symbols
Description: Establish prediction intervals for acuity tests
Study NCT03939871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvestrant + oral vinorelbine
Description: Eligible patients will be treated with the fluvestrant + oral vinorelbine regimen until the disease progresses or intolerable toxicity
Study NCT02023099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267
Study NCT02023099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-450/r/ABT-267
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267
Study NCT02023099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT05055141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care to Share poster
Description: The Care to Share poster enabled patients to share written information about who they are as people with their hospital caregivers.
Study NCT00847223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZARNESTRA (Tipifarnib)
Study NCT01358175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (75 mg)
Description: Secukinumab (75 mg)
Study NCT01358175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (150 mg)
Description: Secukinumab (150 mg)